Remission of metastatic cervical adenocarcinoma with weekly paclitaxel.

Abstract

We report the use of paclitaxel in the successful treatment of a patient with recurrent adenocarcinoma of the cervix. Paclitaxel, 70 mg/m2 by 1-h infusion weekly, was administered to a 59-year-old patient with cervical adenocarcinoma showing lung metastasis. She showed partial clinical response after seven cycles, and at the completion of 20 cycles she showed complete response, which was confirmed by chest X-ray and computed tomography scan. Toxicities including neurotoxicity were mild. She showed an objective response to treatment for over 8 months, and she enjoyed a favorable quality of life during and after treatment. Weekly paclitaxel was very well tolerated, yet was effective for recurrent cervical adenocarcinoma.

• Authors: S Ota, T Sugiyama, K Ushijima, K Fujiyoshi, K Komai, N Hirai, T Nishida, T Kamura
• Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) 2001 Mar-Apr Vol. 11 Issue 2 Pg. 167-8 ISSN: 1048-891X [Print] England
• PMID: 11328417 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Paclitaxel

Topics

• Adenocarcinoma (drug therapy, pathology, secondary)
• Antineoplastic Agents, Phytogenic (administration & dosage, therapeutic use)
• Drug Administration Schedule
• Female
• Humans
• Lung Neoplasms (secondary)
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Paclitaxel (administration & dosage, therapeutic use)
• Uterine Cervical Neoplasms (drug therapy, pathology)